GHP Q3 2021

GHP / Q3 2021 19 , Comprehensive Compliance Solutions for Medical Technology Pharmalex GmbH is a company that has been growing naturalistically and on a global scale, providing regulatory compliance for amyriad of diverse clients across the industries of pharmaceutical product development, biotech, andmedical devices. It is this work that has earned it the ‘Best Medical Device Development and Regulatory Strategy Company’ award for the USA in 2021, and we touched base with the company itself to find out just what about it has earned it somuch trust. Supporting the pharmaceutical, biotechnology, and medical device sectors of its industry, Pharmalex ensures that the companies in these categories are serving their market segments with compliant and safe products throughout every stage of their product lifecycle. Fundamentally, its services entail the quality and regulatory support of clinical and non-clinical development, as well as market authorisations, post market activities, and medical affairs, supporting companies to make sure that each detail is seen to throughout their journey to greater success. Furthermore, this follows its ethos of providing flexible, costeffective solutions for all budding medical technology companies, enabling new products and innovations to be brought to the market. This will be increasingly invaluable as the medical sector continues to adapt and change in the face of the post-Covid19 worldwide paradigm, enabling the development, manufacture, and quality assurance of diagnostic, treatment, and patient wellbeing focused technologies at an improved rate. It also helps its clients to be confident about the products they have developed. By following their motto at every step of the development process, it strives to help its clientele meet and exceed regulatory compliance standards in order to make their products the cutting edge of the latest and greatest, in order to help medical technologies meet, maintain and exceed compliance requirements, capitalizing on greater efficiency and less complexity through its regulatory lifecycle. Additionally, in order to do this, Pharmalex has ensured that its growth has taken place upon a few keystone pillars: its work promises to be flexible; and it delivers subject matter experts and tailored solutions that will always be exactly relevant to what a client wishes to bring to the table. In this manner, part of Pharmalex core is using Technology Enabled Solutions to ensure that it has the innovative solution needed to help a company manage risks and optimize their processes across the board, allowing the products they have developed to quickly prove the competence and reliability of the work behind them from the testing to the market value. It is also driven by a passion for its work. Its team thrives on navigating complex regulatory environments, and its efficiency and dedication in doing so has been widely lauded as exemplary. Essentially, each of these principles allow Pharmalex to provide expert, first-class, intelligent solutions that focus in on supporting a client through tactical support, preferred provider models, and strategic collaborative partner models, derived from its commitment to its core values and made possible by its 1,700 employees across 45 offices. In addition, its experts are capable of handling the entire continuum of regulatory needs for medical devices, IVDs and diagnostic technologies, and Pharmalex thanks each and every one of them for their continued commitment to the client and the industry. In return, Pharmalex supports its colleagues with the maintenance of a global support network, allowing them to communicate with people across a range of disciplines. The result of this is a staff with many exciting avenues available when it comes to their professional development, and Pharmalex finds it an incredibly important aspect of its business model that its staff are as well looked after as its clients, ensuring the continued success of the company as a whole. Lastly, with business having increased over the past year, Pharmalex plans to continue using its current growth spurt as a springboard to further development, maintaining its current projects and pushing on with its virtual support and remote work. Company: Pharmalex GmbH Website: Email: [email protected]